Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Respir Res ; 12: 12, 2011 Jan 19.
Artículo en Inglés | MEDLINE | ID: mdl-21247482

RESUMEN

BACKGROUND: A sizeable body of data demonstrates that membrane ICAM-1 (mICAM-1) plays a significant role in host defense in a site-specific fashion. On the pulmonary vascular endothelium, mICAM-1 is necessary for normal leukocyte recruitment during acute inflammation. On alveolar epithelial cells (AECs), we have shown previously that the presence of normal mICAM-1 is essential for optimal alveolar macrophage (AM) function. We have also shown that ICAM-1 is present in the alveolar space as a soluble protein that is likely produced through cleavage of mICAM-1. Soluble intercellular adhesion molecule-1 (sICAM-1) is abundantly present in the alveolar lining fluid of the normal lung and could be generated by proteolytic cleavage of mICAM-1, which is highly expressed on type I AECs. Although a growing body of data suggesting that intravascular sICAM-1 has functional effects, little is known about sICAM-1 in the alveolus. We hypothesized that sICAM-1 in the alveolar space modulates the innate immune response and alters the response to pulmonary infection. METHODS: Using the surfactant protein C (SPC) promoter, we developed a transgenic mouse (SPC-sICAM-1) that constitutively overexpresses sICAM-1 in the distal lung, and compared the responses of wild-type and SPC-sICAM-1 mice following intranasal inoculation with K. pneumoniae. RESULTS: SPC-sICAM-1 mice demonstrated increased mortality and increased systemic dissemination of organisms compared with wild-type mice. We also found that inflammatory responses were significantly increased in SPC-sICAM-1 mice compared with wild-type mice but there were no difference in lung CFU between groups. CONCLUSIONS: We conclude that alveolar sICAM-1 modulates pulmonary inflammation. Manipulating ICAM-1 interactions therapeutically may modulate the host response to Gram negative pulmonary infections.


Asunto(s)
Acrilamidas/metabolismo , Células Epiteliales/inmunología , Inmunidad Innata , Infecciones por Klebsiella/inmunología , Klebsiella pneumoniae/patogenicidad , Neumonía Bacteriana/inmunología , Alveolos Pulmonares/inmunología , beta-Alanina/análogos & derivados , Animales , Células Cultivadas , Quimiocina CXCL2/metabolismo , Quimiotaxis , Modelos Animales de Enfermedad , Células Epiteliales/microbiología , Mediadores de Inflamación/metabolismo , Infecciones por Klebsiella/genética , Infecciones por Klebsiella/microbiología , Macrófagos Alveolares/inmunología , Macrófagos Alveolares/microbiología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Fagocitosis , Neumonía Bacteriana/genética , Neumonía Bacteriana/microbiología , Regiones Promotoras Genéticas , Alveolos Pulmonares/microbiología , Proteína C Asociada a Surfactante Pulmonar/genética , Factores de Tiempo , Factor de Necrosis Tumoral alfa/metabolismo , Regulación hacia Arriba , beta-Alanina/genética , beta-Alanina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA